The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials

被引:33
作者
Tabrizi, Reza [1 ]
Tamtaji, Omid Reza [2 ]
Lankarani, Kamran B. [3 ]
Mirhosseini, Naghmeh [4 ]
Akbari, Maryam [1 ]
Dadgostar, Ehsan [5 ]
Peymani, Payam [3 ]
Asemi, Zatollah [6 ]
机构
[1] Shiraz Univ Med Sci, Inst Hlth, Hlth Policy Res Ctr, Student Res Comm, Shiraz, Iran
[2] Kashan Univ Med Sci, Physiol Res Ctr, Kashan, Iran
[3] Shiraz Univ Med Sci, Inst Hlth, Hlth Policy Res Ctr, Shiraz, Iran
[4] Pure North Senergy Fdn, Calgary, AB, Canada
[5] FDA, Halal Res Ctr IRI, Tehran, Iran
[6] Kashan Univ Med Sci, Res Ctr Biochem & Nutr Metab Dis, Kashan, Iran
关键词
C-REACTIVE PROTEIN; BLOOD MONONUCLEAR-CELLS; CLINICAL-TRIAL; CARDIOVASCULAR-DISEASE; INSULIN SENSITIVITY; PRIMARY PREVENTION; GENE-EXPRESSION; DOUBLE-BLIND; IMPROVES; GLUCOSE;
D O I
10.1039/c8fo01259h
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There are several current trials investigating the effect of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome (MetS); however, their findings are controversial. This systematic review and meta-analysis of randomized controlled trials (RCTs) were conducted to summarize the existing evidence and collectively determine the effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with MetS and related disorders. Two authors independently searched electronic databases, including MEDLINE, EMBASE, Cochrane Library, and Web of Science databases, until May 2018 in order to find relevant RCTs. The quality of the selected RCTs was evaluated using the Cochrane Collaboration risk of bias tool. Cochran's Q test and I-square (I-2) statistic were used to determine whether heterogeneity exists across included trials. Standardized mean difference (SMD) and 95% CI between two intervention groups were used to determine pooled effect sizes. Out of 317 potential citations selected based on keywords, 24 RCTs met the inclusion criteria and were eligible for the current meta-analysis. The pooled results obtained by using the random-effects model showed that resveratrol supplementation significantly decreased C-reactive protein (CRP) (SMD = -0.55; 95% CI, -0.84, -0.26; P < 0.001; I-2: 84.0) and tumor necrosis factor- (TNF-) (SMD = -0.68; 95% CI, -1.08, -0.28; P = 0.001; I-2: 81.3) concentrations among patients with MetS and related disorders. Interleukin 6 (IL-6) (SMD = 0.05; 95% CI, -0.31, 0.41; P = 0.79; I-2: 85.0) and superoxide dismutase (SOD) (SMD = 0.21; 95% CI, -3.16, 3.59; P = 0.90; I-2: 97.7) concentrations did not significantly change following resveratrol supplementation. Resveratrol supplementation showed a promising lowering effect on some of the inflammatory markers among patients with MetS and related disorders. Additional prospective studies regarding the effect of resveratrol supplementation on biomarkers of inflammation and oxidative stress by using higher doses of resveratrol and longer duration of supplementation are necessary.
引用
收藏
页码:6117 / 6129
页数:13
相关论文
共 51 条
[1]   Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity [J].
Alberti, K. G. M. M. ;
Eckel, Robert H. ;
Grundy, Scott M. ;
Zimmet, Paul Z. ;
Cleeman, James I. ;
Donato, Karen A. ;
Fruchart, Jean-Charles ;
James, W. Philip T. ;
Loria, Catherine M. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2009, 120 (16) :1640-1645
[2]  
Ardelean F., 1982, FIZIOLOGIA PHYSL, V96, P32
[3]   Impact of Body Mass Index and the Metabolic Syndrome on the Risk of Cardiovascular Disease and Death in Middle-Aged Men [J].
Arnlov, Johan ;
Ingelsson, Erik ;
Sundstrom, Johan ;
Lind, Lars .
CIRCULATION, 2010, 121 (02) :230-U88
[4]  
Bashmakov Yuriy K, 2014, ISRN Endocrinol, V2014, P816307, DOI 10.1155/2014/816307
[5]  
Bhatt JK, 2013, Int. Res. J. Pharm, V4, P245, DOI DOI 10.7897/2230-8407.04849
[6]   A combination of isolated phytochemicals and botanical extracts lowers diastolic blood pressure in a randomized controlled trial of hypertensive subjects [J].
Biesinger, S. ;
Michaels, H. A. ;
Quadros, A. S. ;
Qian, Y. ;
Rabovsky, A. B. ;
Badger, R. S. ;
Jalili, T. .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2016, 70 (01) :10-16
[7]   Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial [J].
Bo, S. ;
Ponzo, V. ;
Ciccone, G. ;
Evangelista, A. ;
Saba, F. ;
Goitre, I. ;
Procopio, M. ;
Pagano, G. F. ;
Cassader, M. ;
Gambino, R. .
PHARMACOLOGICAL RESEARCH, 2016, 111 :896-905
[8]   Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients [J].
Brasnyo, Pal ;
Molnar, Gergo A. ;
Mohas, Marton ;
Marko, Lajos ;
Laczy, Boglarka ;
Cseh, Judit ;
Mikolas, Esztella ;
Szijarto, Istvan Andras ;
Merei, Akos ;
Halmai, Richard ;
Meszaros, Laszlo G. ;
Suemegi, Balazs ;
Wittmann, Istvan .
BRITISH JOURNAL OF NUTRITION, 2011, 106 (03) :383-389
[9]   Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease [J].
Chachay, Veronique S. ;
Macdonald, Graeme A. ;
Martin, Jennifer H. ;
Whitehead, Jonathan P. ;
O'Moore-Sullivan, Trisha M. ;
Lee, Paul ;
Franklin, Michael ;
Klein, Kerenaftali ;
Taylor, Paul J. ;
Ferguson, Maree ;
Coombes, Jeff S. ;
Thomas, Gethin P. ;
Cowin, Gary J. ;
Kirkpatrick, Carl M. J. ;
Prins, Johannes B. ;
Hickman, Ingrid J. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (12) :2092-U383
[10]  
Chekalina N., 2016, Wiad Lek, V69, P475